Condition: Breast Cancer · Liver Metastases · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.
This description comes directly from the study's public registry record.
Amelia Mattia, MD · +390453015 · amelia.mattia01@icatt.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome, Lazio, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06093022